Prosecution Insights
Last updated: November 20, 2026
Application No. 18/800,202

ACCESSORY-BASED STORAGE FOR USE WITH A MEDICAL DEVICE

Non-Final OA §102§103§DOUBLEPATENT
Filed
Aug 12, 2024
Priority
Nov 15, 2019 — provisional 62/935,849 +2 more
Examiner
BERTRAM, ERIC D
Art Unit
3792
Tech Center
3700 — Mechanical Engineering & Manufacturing
Assignee
ZOLL Medical Corporation
OA Round
1 (Non-Final)
81%
Grant Probability
Favorable
1-2
OA Rounds
10m
Est. Remaining
93%
With Interview

Examiner Intelligence

Grants 81% — above average
81%
Career Allowance Rate
1058 granted / 1302 resolved
+11.3% vs TC avg
Moderate +12% lift
Without
With
+11.9%
Interview Lift
resolved cases with interview
Typical timeline
3y 2m
Avg Prosecution
49 currently pending
Career history
1354
Total Applications
across all art units

Statute-Specific Performance

§101
4.1%
-35.9% vs TC avg
§103
35.8%
-4.2% vs TC avg
§102
29.8%
-10.2% vs TC avg
§112
12.4%
-27.6% vs TC avg
Black line = Tech Center average estimate • Based on career data from 1302 resolved cases

Office Action

§102 §103 §DOUBLEPATENT
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Information Disclosure Statement The information disclosure statement (IDS) submitted on 10/24/2024 was filed in compliance with the provisions of 37 CFR 1.97. Accordingly, the information disclosure statement is being considered by the examiner. Specification The disclosure is objected to because of the following informalities: in the first paragraph, the continuity data should be updated to indicate that US App. No. 18/330,820 is now US Patent No. 12,083,350. Appropriate correction is required. Double Patenting The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the “right to exclude” granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory double patenting rejection is appropriate where the conflicting claims are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., In re Berg, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); In re Goodman, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); In re Longi, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); In re Van Ornum, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); In re Vogel, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); In re Thorington, 418 F.2d 528, 163 USPQ 644 (CCPA 1969). A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on nonstatutory double patenting provided the reference application or patent either is shown to be commonly owned with the examined application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement. See MPEP § 717.02 for applications subject to examination under the first inventor to file provisions of the AIA as explained in MPEP § 2159. See MPEP § 2146 et seq. for applications not subject to examination under the first inventor to file provisions of the AIA . A terminal disclaimer must be signed in compliance with 37 CFR 1.321(b). The filing of a terminal disclaimer by itself is not a complete reply to a nonstatutory double patenting (NSDP) rejection. A complete reply requires that the terminal disclaimer be accompanied by a reply requesting reconsideration of the prior Office action. Even where the NSDP rejection is provisional the reply must be complete. See MPEP § 804, subsection I.B.1. For a reply to a non-final Office action, see 37 CFR 1.111(a). For a reply to final Office action, see 37 CFR 1.113(c). A request for reconsideration while not provided for in 37 CFR 1.113(c) may be filed after final for consideration. See MPEP §§ 706.07(e) and 714.13. The USPTO Internet website contains terminal disclaimer forms which may be used. Please visit www.uspto.gov/patent/patents-forms. The actual filing date of the application in which the form is filed determines what form (e.g., PTO/SB/25, PTO/SB/26, PTO/AIA /25, or PTO/AIA /26) should be used. A web-based eTerminal Disclaimer may be filled out completely online using web-screens. An eTerminal Disclaimer that meets all requirements is auto-processed and approved immediately upon submission. For more information about eTerminal Disclaimers, refer to www.uspto.gov/patents/apply/applying-online/eterminal-disclaimer. Claims 161, 162, 168-172, 175 and 177-181 are rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1-31 of U.S. Patent No. 11,712,574. Although the claims at issue are not identical, they are not patentably distinct from each other because the patented claims anticipate the current claims. Claims 163-166 are rejected on the ground of nonstatutory double patenting as being unpatentable over the patented claims in view of Jensen et al. (US 9,844,658, hereinafter Jensen). Regarding claims 163-166, the patented claims disclose the applicant’s basic invention but is silent as to the connection between the electrode and the defibrillators being a short-range wireless connection. Attention is directed to the Jensen reference, which discloses that defibrillation electrodes can utilize a Bluetooth connection to communicate ECG timing signals with defibrillation devices (Col. 9, lines 22-61 and Col. 20, lines 32-41). Bluetooth is a battery powered system that inherently works by detecting the presence of, and establishing a connection with, nearby Bluetooth devices. Therefore, it would have been obvious to one of ordinary skill in the art before the applicant’s effective filing date to modify the patented claims to utilize the Bluetooth connection of Jensen as substituting the wireless connection of Jensen for the connection of the patented claims would not affect the overall operation or purpose of the patented claims. Claims 161, 162, 168-172, 175 and 179-181 are rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1-23 of U.S. Patent No. 12,083,350. Although the claims at issue are not identical, they are not patentably distinct from each other because the patented claims anticipate the current claims. Claims 163-166, 177 and 178 are rejected on the ground of nonstatutory double patenting as being unpatentable over the patented claims in view of Jensen et al. (US 9,844,658, hereinafter Jensen). Regarding claims 163-166, 177 and 178, the patented claims disclose the applicant’s basic invention but is silent as to the connection between the electrode and the defibrillators being a short-range wireless connection. Attention is directed to the Jensen reference, which discloses that defibrillation electrodes can utilize a Bluetooth connection to communicate ECG timing signals with defibrillation devices (Col. 9, lines 22-61 and Col. 20, lines 32-41). Bluetooth is a battery powered system that inherently works by detecting the presence of, and establishing a connection with, nearby Bluetooth devices. Therefore, it would have been obvious to one of ordinary skill in the art before the applicant’s effective filing date to modify the patented claims to utilize the Bluetooth connection of Jensen as substituting the wireless connection of Jensen for the connection of the patented claims would not affect the overall operation or purpose of the patented claims. Claim Rejections - 35 USC § 102 In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless – (a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention. Claims 161-162, 168-171, 175 and 181 are rejected under 35 U.S.C. 102(a)(1) as being anticipated by Prew et al. (US 2015/0094782, hereinafter Prew). Regarding claims 161-162, 168-171, 175 and 181, Prew discloses a patient-coupled treatment device 250/310 for use with a plurality of medical devices 300 (par. 0038-0039, 0044). The treatment device includes a defibrillation electrode 250/310 with a skin contacting portion configured to provide treatment to a patient (par. 0037-0039). A connector 315/320/415 is configured to electrically connect the patient-coupled treatment device to one or more medical devices, including a first defibrillator 300 and a second defibrillator 400 (par. 0039, 0044-0045). A housing of the treatment device includes a non-volatile memory 290 and associated circuitry 275 (par. 0037 and figure 2). Using a first communication connection with the first defibrillator, the memory and circuitry are configured to record and store a device identifier of the treatment device [including storing a type and model/serial number of the treatment device (par. 0036-0037)] readable by the first and/or second defibrillators, as well as treatment information received from the first defibrillator prior to and/or during treatment of the patient, including shock information (i.e., “rescuer treatment information”) (par. 0017, 0037-0038, 0041). The stored information can be transferred to the second defibrillator upon detecting a second communication conneciton with the second defibrillator (par. 0041, 0045-0046). Claim Rejections - 35 USC § 103 In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. The factual inquiries for establishing a background for determining obviousness under 35 U.S.C. 103 are summarized as follows: 1. Determining the scope and contents of the prior art. 2. Ascertaining the differences between the prior art and the claims at issue. 3. Resolving the level of ordinary skill in the pertinent art. 4. Considering objective evidence present in the application indicating obviousness or nonobviousness. This application currently names joint inventors. In considering patentability of the claims the examiner presumes that the subject matter of the various claims was commonly owned as of the effective filing date of the claimed invention(s) absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and effective filing dates of each claim that was not commonly owned as of the effective filing date of the later invention in order for the examiner to consider the applicability of 35 U.S.C. 102(b)(2)(C) for any potential 35 U.S.C. 102(a)(2) prior art against the later invention. Claims 163-166, 177 and 178 are rejected under 35 U.S.C. 103 as being unpatentable over Prew in view of Jensen et al. (US 9,844,658, hereinafter Jensen). Regarding claims 163-166, Prew discloses the applicant’s basic invention but is silent as to the connection between the electrode and the defibrillators being a short-range wireless connection. Attention is directed to the Jensen reference, which discloses that defibrillation electrodes can utilize a Bluetooth connection to communicate ECG timing signals with defibrillation devices (Col. 9, lines 22-61 and Col. 20, lines 32-41). Bluetooth is a battery powered system that inherently works by detecting the presence of, and establishing a connection with, nearby Bluetooth devices. Therefore, it would have been obvious to one of ordinary skill in the art before the applicant’s effective filing date to modify Prew to utilize the Bluetooth connection of Jensen as substituting the wireless connection of Jensen for the connection of Prew would not affect the overall operation or purpose of Prew. Claims 172 and 179-180 are rejected under 35 U.S.C. 103 as being unpatentable over Prew in view of Powers et al. (US 6,360,120, hereinafter Powers). Regarding claims 172 and 179-180, Prew discloses a patient-coupled treatment device 250/310 (i.e., an electrode) for use with a plurality of medical devices 300 (par. 0038-0039, 0044). The treatment device includes a defibrillation electrode 250/310 configured to provide treatment to a patient (par. 0037-0039). A connector 315/320/415 is configured to electrically connect the patient-coupled treatment device to one or more medical devices, including a first defibrillator 300 and a second defibrillator 400 (par. 0039, 0044-0045). A housing of the treatment device includes a non-volatile memory 290 and associated circuitry 275 (par. 0037 and figure 2). The memory and circuitry are configured to record and store a device identifier of the treatment device readable by the first and/or second defibrillators, as well as treatment information received from the first defibrillator prior to and/or during treatment of the patient, including shock information (i.e., “rescuer treatment information”) (par. 0017, 0037-0038, 0041). The stored information can be transferred to the second defibrillator upon detecting an electrical connection with the second defibrillator (par. 0041, 0045-0046). Furthermore, Prew discloses that the electrodes can be used to record ECG signals from the patient (par. 0038). As is known to one of ordinary skill in the art, ECG signals are continuous, sequential electrical signals. Therefore, an ECG signal necessarily includes timing information, as it will, for example, show a Q wave occurring after a P wave, and it will show each individual heart beat in sequence. The claims do not define the timing information as being separate/distinct from the medical treatment information. However, Prew does not explicitly recite that the ECG signals are received by the connector. Attention is directed to Powers, which also discloses a patient-coupled treatment device 36 (i.e., an electrode) for use with a plurality of medical devices 10/100, and thus is analogous art with Prew (figure 1a and Col. 3, lines 50-55). The treatment device includes a patient-coupled portion 28 configured to provide treatment to a patient (Col. 3, lines 59-64). A connector 26 is configured to electrically connect the patient-coupled treatment device to one or more medical devices 10/100 (Col. 3, lines 49-55). A housing of the treatment device includes a non-volatile memory 32 and associated circuitry (Fig. 1a and Col. 3, lines 31-43, Col. 4, lines 7-30 and Col. 5, lines 3-20). The memory and circuitry are configured to record and store treatment information received from the medical device, including ECG data (i.e., patient history information) over an elapsed time period and treatment delivered, as well as the inherent timing of the ECG data, as described above (Col. 4, lines 7-30). The stored information can be transferred to a second medical device for retrieval and use by advanced caregivers (Col. 6, lines 59-63). Therefore, it would have been obvious to one of ordinary skill in the art before the applicant’s effective filing date to modify Prew to record and store the ECG signal of the medical treatment information in the connector as taught by Powers in order to provide as much data as possible to by the advanced caregiver (Col. 6, lines 55-64 of Powers for motivation). Allowable Subject Matter Claim 167 is objected to as being dependent upon a rejected base claim, but would be allowable if rewritten in independent form including all of the limitations of the base claim and any intervening claims, and if a Terminal Disclaimer were filed to overcome the double patenting rejection. Conclusion The prior art made of record and not relied upon is considered pertinent to applicant's disclosure. See attached PTO-892 especially US 7,016,726 which discloses communicating with electrodes. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Eric D Bertram whose telephone number is (571)272-3446. The examiner can normally be reached Monday-Friday 8am-6pm Central Time. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Jennifer McDonald can be reached on 571-270-3061. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /Eric D. Bertram/Primary Examiner, Art Unit 3796
Read full office action

Prosecution Timeline

Aug 12, 2024
Application Filed
Nov 06, 2026
Non-Final Rejection mailed — §102, §103, §DOUBLEPATENT (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12796927
Systems, Devices, Components and Methods for Detecting the Locations of Sources of Cardiac Rhythm Disorders in a Patient's Heart
3y 0m to grant Granted Nov 17, 2026
Patent 12788980
NANOSECOND PULSED ELECTRIC FIELD SYSTEM
2y 9m to grant Granted Nov 10, 2026
Patent 12788296
Wearable Multi-Modal Sensing Device for Real-Time Neurological Monitoring and Disorder Detection
1y 10m to grant Granted Nov 10, 2026
Patent 12779235
WEARABLE CARDIOVERTER DEFIBRILLATOR (WCD) SYSTEM REACTING TO HIGH-AMPLITUDE ECG NOISE
3y 6m to grant Granted Nov 03, 2026
Patent 12773565
IMPLANTABLE MEDICAL DEVICES FOR MULTI-CHAMBER PACING
3y 5m to grant Granted Oct 27, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
81%
Grant Probability
93%
With Interview (+11.9%)
3y 2m (~10m remaining)
Median Time to Grant
Low
PTA Risk
Based on 1302 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month